Official Title Depressive Episodes Associated with Bipolar I or II Disorder: A Double-Blind,
Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of
ABBV-932

Purpose

The purpose of this study is to see if the investigational study drug is safe and useful for treating patients with bipolar depression.

Eligible participants will be randomized to receive the drug or placebo. A placebo looks just like the investigational study drug but has no active drug in it.

The maximum duration of the study treatment period is 6 weeks. Participants receive psychiatric evaluation at each visit, and physical exam, urine test and blood draws at some of the visits. All study medication and procedures are provided at no cost, and participants may be compensated for their time and travel for each visit attended.

Could this study be right for you?

A diagnosis of bipolar disorder (type I or II) and be currently depressed.

Age Range

18 - 65 years

Official Title A Multicenter, Randomized, Double-Blind, Parallel-Group
Dose-Controlled Study Evaluating the Safety and Efficacy of
RE104 for Injection in the Treatment of Patients with
Postpartum Depression (PPD)

Purpose

The purpose of this study is to compare the effectiveness of two doses of an experimental medication, administered once, in reducing symptoms of depression in patients with postpartum depression.

 

Eligible participants will be assigned by chance to one of the two doses of the medication. The study includes 6 in-person visits and 4 telephone calls for up to 8 weeks.

Could this study be right for you?

To be eligible for this study, participants must meet the following criteria:

• Female aged 18 to 45 years
• Less than 12 months since delivery
• Currently depressed
• Not currently breastfeeding

Age Range

18 - 45 years

Official Title A Phase III, multicentre, randomised, double-blind,
controlled study to investigate the efficacy, safety,
and tolerability of two initial administrations of
COMP360 in participants with treatment-resistant
depression

Purpose

The study investigates a new approach for treatment-resistant depression using an investigational medicine related to psilocybin alongside psychological support.

Could this study be right for you?

You may be able to join the study if you:

—         Are 18 years of age or older

—         Have been diagnosed with major depression and have not responded to 2+ antidepressants

Other criteria will need to be met to confirm your eligibility for this study, which will last up to 62 weeks.

Age Range

18 years and up

Official Title A Randomized, Double-Blind, Placebo-controlled Multicenter Study to Assess the
Efficacy and Safety of Lumateperone as Adjunctive Therapy in the Treatment of
Patients with Major Depressive Disorder

Purpose

Depression is one of the most common mental health issues worldwide. Many people with major depressive disorder (MDD) take antidepressant medications that do not provide enough of a response to ease their depressive symptoms.

The primary objective of this study is to evaluate the benefit of Lumateperone 42 mg administered once daily compared with placebo as adjunctive treatment to antidepressant therapy (ADT) in patients with Major Depressive Disorder (MDD) who have an inadequate response to ongoing ADT.

Could this study be right for you?

You may be able to take part if you:

• are 18–65 years of age

• have a confirmed diagnosis of Major Depressive Disorder (MDD)

• feel that your current antidepressant medication is not working well

• Has tried 2 or more antidepressant medication in the current episode of depression

 

Other criteria will need to be met to confirm your eligibility for this study.

Age Range

18 - 65 years

Official Title Evaluation of Wear Experience with PRECISION7® For Astigmatism Contact Lenses in Neophyte Lens Wearers

Purpose

The purpose of this study is to explore the wear experience with PRECISION7® For Astigmatism lenses in adults who have not previously worn contact lenses.

Could this study be right for you?

1. Adults who have never worn contact lenses.
2. Adults who have astigmatism
3. Ability to attend 3 visits over the course of 3 weeks.
4. Satisfy all other study eligibility and exclusion criteria.

Age Range

18 - 40 years

Official Title The KOBRA Study: The Effects of Knee Osteoarthritis on Brain Activation

Purpose

The purpose of this study is to assess changes in brain activation and processing in those with right knee osteoarthritis compared to healthy controls. 

Could this study be right for you?

• Either two healthy knees OR those with right knee pain from a diagnosis of right knee osteoarthritis with a healthy left knee
• No metal implants that prevent you from having an MRI
• No foot/ankle/leg/hip surgeries in the past year
• No neurologic conditions
• No conditions that prevent athletic participation or maximal effort exercise
• Able to provide informed consent
• Speak and read English

Age Range

45 - 70 years

Official Title Establishing Reference Values and Clinical Decision Points for Quantitative Videofluoroscopic Measures of Swallowing

Purpose

This study will help create healthy reference values clinicians can use to evaluate adult patients of all ages and is sponsored by the National Institute on Aging.  During this study, we will perform an x-ray swallowing exam and breathing tests with persons who do not have a personal history of swallowing problems or any disorders that could contribute to a swallowing problem.  Study participation will consist of a screening meeting (approximately 15 minutes) via phone call, video chat, or email to verify eligibility, and one in-person visit to our laboratory (approximately 1 hour).

Could this study be right for you?

• If you are biologically female and of child-bearing age (<63), you must not be pregnant or breastfeeding.
• No personal history of surgery or radiation therapy to the head or neck (mouth, jaw, neck, brain, nose, face, thyroid, throat, or voice box) other than having your tonsils, adenoids, or teeth removed.
• No personal history of cancer involving structures of the head, neck, spine, respiratory, or lymphatic system.
• No personal history of stroke or other progressive nerve disease.
• No current diagnosis or personal history of Chronic Obstructive Pulmonary Disease (COPD).
• No known allergies to barium.

Age Range

54 - 89 years

Official Title A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study to Evaluate the Efficacy and Safety of ESK-001 in Patients with Moderate to Severe Plaque Psoriasis (ONWARD1)

Purpose

The purpose of this study is to evaluate the efficacy of ESK-001 

There may be a chance that you will be asked to come into the study site for unscheduled study visits that may include extra tests to assess for your safety.

The duration of the study will be a minimum of 28 weeks, if you participate in the long-term extension study, or 32 weeks if instead you enter the follow-up period. You will need to come to the study site at least 10 or 11 times respectively over this period. 

Could this study be right for you?

• Subject must have a diagnosis of plaque psoriasis for at least 6 months 
• Subjects must not have other immune-mediated conditions such as uveitis and inflammatory bowel disease (patients with psoriatic arthritis may participate) 
• Subject must be in good general health with no history of tuberculosis, cancer, HIV, hepatitis B or C
• Subjects must have no history of unstable cardiac disease (for example, unstable angina or rapid atrial fibrillation) or cardiac hospitalization within 3 months 
• Female subjects must not be pregnant or considering becoming pregnant for the duration of the study 

Age Range

18 years and up

Official Title The Development of Semantic Organization

Purpose

We are currently in the process of conducting a 5-year National Institutes of Health-funded longitudinal study on semantic and language development, specifically focusing on how children learn new words and understand their meanings. Our goal is to not only examine language learning but also how these processes evolve as children grow.

In this study, we will follow two hundred 4-year-old junior scientists as they participate in fun, interactive word-learning and language activities. Over the course of the study, participants will visit our lab twice a year, each lasting around 60-90 minutes (including breaks), to engage in a series of playful games with a research assistant designed to explore how children comprehend and retain new vocabulary. Additionally, your child will have the opportunity to wear a LENA recorder—a small, wearable device that tracks the number of words your child hears throughout the day, similar to a Fitbit but for words!

 

Could this study be right for you?

• Child must be monolingual
• Not born premature
• No developmental delays
• Can give a verbal response
• Normal to corrected vision

Age Range

4 - 4 years

Official Title Neural Biomarkers of Sensory Symptoms in Autism

Purpose

The purpose of this study is to understand sensory processing in children on the autism spectrum, Using EEG, we will look at brainwaves while children play different computer games. We will also have children play some paper-pencil games during their visit to our lab. We hope to better understand sensory experiences and support autistic people in ways that celebrate their unique strengths.

Could this study be right for you?

Inclusion criteria for the autism group are

• Diagnosis of autism from a licensed psychologist based on the Autism Diagnostic Interview-Revised or the Autism Diagnostic Observation Schedule (ADOS),
• Aged 8 - 12 years old
• Normal/corrected vision/hearing, and IQ > 65. 19 Children taking stimulant medications will be included in the study but will be required to be off medication for 24 (for short-acting preparations) to 48 h (long-acting preparations) prior to the visit 

Inclusion criteria for the age-matched TD control group include:

• No concerns/diagnoses of any neurodevelopmental, learning, or mental health conditions 

Age Range

8 - 12 years

Official Title A Multi-center, Phase 1/2a, First-in-human (FIH) Study Investigating the Safety, Tolerability, and Efficacy of AMT-260 in Adults with Unilateral Refractory Mesial Temporal Lobe Epilepsy (MTLE) Administered via Magnetic Resonance Imaging (MRI)-guided Convection-enhanced Delivery (CED)

Purpose

You are being invited to participate in a study about mesial temporal lobe epilepsy (MTLE) on only 1 side (unilateral) of the brain that has not responded to medication (refractory).

The study will test AMT-260, which is a new gene therapy under investigation for use in treating people like you with MTLE. It is not yet approved as a drug for treating MTLE. It can only be used in a study like this one. This is the first time this gene therapy will be used in humans. It has previously been studied in animals.

AMT-260 is a gene therapy designed to reduce the electrical signals between nerve cells (neurons) in the parts of your brain where nerve cells are abnormally connected. This reduces the extra electrical signals that happen at the same time and is intended to reduce your seizure activity.

The overall goals of this study are:

• To observe whether participants have any side effects from AMT-260 or from the procedure to deliver AMT-260 into the brain and how well participants tolerate any side effects that may occur.
• To measure if participants have changes in:
  • frequency of their seizures
  • how their seizures affect their life
  • how the human body takes up and removes AMT-260
• To find the best dose of AMT-260 for future participants to ensure clinical benefit with minimal or no side effects.

Could this study be right for you?

Adult, 18-65 years of age, inclusive, capable of giving informed consent.
Written informed consent is given freely after the nature of the study has been explained to the participant and the completion of data disclosure.
Willingness to undergo necessary surgical procedures.
Diagnosis of unilateral refractory MTLE for ≥360 days, confirmed by an Epilepsy Monitoring Unit.

Additional Eligibility Criteria to be assessed by neurosurgery team, and as described in the study protocol.

Age Range

18 - 65 years

Official Title Developing Rumination-Focused Treatment to Reduce Risk for Depression Recurrence (RDR) in Adolescence (RuMeChange)

Purpose

We are conducting a study looking at how therapy strategies can help teenagers stay healthy, reduce rumination, or overthinking and worrying, and prevent depression relapse. If eligible, the teenager would complete assessments which include clinical interviews over Zoom, surveys, cognitive testing, and an MRI.

A parent/guardian is required to enroll in the study and will complete questionnaires and a clinical interview as well.

Could this study be right for you?

Inclusion Criteria:

• 14-17 years of age at enrollment
• Youth assent and parent consent

Exclusion Criteria:

• Metal braces, tattoos with metal
• Claustrophobia
• Current pregnancy

Age Range

14 - 17 years